• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Flowonix warns on software anomaly with Prometra pump

August 30, 2019 By Sean Whooley

Flowonix earlier this month warned about a software anomaly with its Prometra infusion pump that could unexpectedly shut down the device.

The Budd Lake, N.J.-based company won FDA approval in February for updated software included in the Prometra system, which is indicated for intrathecal infusion of drug therapy, including infumorph, saline and baclofen.

Flowonix warned that the pump can unexpectedly shut down if a certain extended programming sequence is used while the device is in “periodic flow” or “multiple rates flow” mode. If the pump shuts down, it abruptly ceases the drug therapy, which can lead to significant reduction in pain relief or withdrawal symptoms.

All reported events were caused by a U.S.-only version of the software and occurred only here, Flowonix said. There were no events reported anywhere outside the U.S., the company said.

Distributors should immediately notify providers who are using the Prometra pumps and healthcare providers should stop using the affected modes and schedule reprogramming for patients who had drugs administered by the pumps.

“We are developing a solution to address all concerns associated with this issue in a new version of the programmer. This will take some time. In the interim, the key safeguard is to stop using demand bolus features while a patient is in a periodic flow or multiple rates flow mode, as this programming sequence has been determined to be a potential cause of this error,” Flowonix said in the August 12 letter.

Filed Under: Drug-Device Combinations, Featured, Pain Management Tagged With: Flowonix

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS